John D Ratliff
CIK 1575951 · CEO, Covance Drug Development · last filed 2019-04-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$32.36M
Companies
2
Total Filings
13
Lifetime Open-Market Net
-$9.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 2 of 2
13 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-10-05 | LH | Grant (A) | — | $0 | EDGAR |
| 2013-11-19 | Q | Mixed | −97,140 | -$8.30M | EDGAR |
| 2013-05-09 | Q | Grant (A) | — | $0 | EDGAR |
Showing 11–13 of 13
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.